New central body and more cash for UK medical R&D (research and development):
This article was originally published in Clinica
This week's UK public spending review has been welcomed by the healthcare technology industries for its focus on science. Of note is the increase in R&D spending compared with GDP, from 1.86% to 2.5% by 2014. The BioIndustry Association welcomed this and other measures, some of which were recommended in the sector's framework report, Bioscience 2015. This includes pledges to improve clinical research infrastructure, backed by the creation of the UK Clinical Research Collaboration (UKCRC). Its launch, last week, came with a £24m ($44.5m) initial research budget. A further £7m will go to equipping infrastructure. Further reviews of clinical research funding are promised before the 2006 spending review.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.